Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXOSOME-MSC for Moderate COVID-19
NCT05216562Phase 3Unknown
- Sponsor
- Dermama Biotechnology Laboratorium
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of Dermama Exosome-MSC in COVID-19 pneumonia, sponsored by Dermama Biotechnology Laboratorium. Status: unknown.
02
Drugs
Dermama Exosome-MSC
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05216562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216562.